Samsung EPIS launches NexLab for new drug R&D

(MK DB)

Samsung EPIS Holdings has launched a new subsidiary, EPIS NexLab, to spearhead next-generation drug research and development, marking the company’s first major step toward future biotech growth.

The holding company, officially established on Nov. 1 after being spun off from Samsung Biologics, said Monday that EPIS NexLab combines the name “EPIS” with “Next Laboratory,” reflecting its focus on future-oriented innovation and flexible research across diverse therapeutic platforms.

EPIS NexLab will develop advanced biotechnology platforms targeting multiple modalities such as peptide-based therapeutics, which offer high specificity and broad applicability beyond single-disease treatments. The company aims to create scalable core technologies capable of generating a wide pipeline of biopharmaceutical candidates.

It plans to expand open innovation by pursuing joint research and technology partnerships with global pharmaceutical firms based on its platform technologies.

Hong Seong-won, who heads Samsung Bioepis‘ Development Division 1, has been appointed as the first CEO while continuing to serve as a board member of Samsung EPIS Holdings. A veteran R&D leader, Hong previously held senior roles at LG Chem and U.S.-based Regeneron Pharmaceuticals, leading major biopharmaceutical development and global approvals.

“EPIS NexLab will drive bold innovation in biotechnology under a stable holding structure and secure new growth engines for Samsung EPIS Holdings,” Hong said.

Samsung EPIS Holdings, which will be relisted on the main Kospi market on Nov. 24, now oversees two key subsidiaries — Samsung Bioepis, focused on developing and commercializing biosimilars, and EPIS NexLab, dedicated to technology platform development.

Samsung Bioepis has launched 11 biosimilars globally to date. Kim Kyung-ah, CEO of Samsung EPIS Holdings, said the company will “continue to build synergy across all business areas and create a success story that improves human life.”